Akers Biosciences Inc (NASDAQ: AKER), which said earlier this week that it is one step closer to identifying a coronavirus vaccine candidate, announced another successful milestone Wednesday in its vaccine development program.
The New Jersey-based company said that it, along with developmental partner Premas Biotech, has successfully completed the second milestone of successful expression of the three coronavirus antigens — spike, envelop and membrane —selected for their vaccine candidate.
Benzinga is covering every angle of how the coronavirus affects the financial world. For daily updates, sign up for our coronavirus newsletter.
"The antigens have been expressed using the D-CryptTM platform at Premas Biotech, which utilizes its vectors and S cerevisiae strain," according to Akers.
Premas will now move ahead with purification and post-expression processing that will lead to a scaling up of the antigen, according to a press release.
The company is now halfway through a four-milestone plan that it believes will lead to the commencement of clinical trials, Akers Executive Chairman Christopher Schreiber said in a statement.
Akers shares were advancing 6.14% to $6.05 at the time of publication Wednesday.
Analyst Projects Over 130% Upside In This Biopharma
Teva Analyst Says Shares Are Pricing In Too Much Risk
See more from Benzinga
- The Daily Biotech Pulse: Mesoblast To Test Candidate On Coronavirus Symptoms, Proxy Battle Ahead For Rockwell Medical, Glaukos to Join S&P SmallCap 600 Index
- The Daily Biotech Pulse: Sangamo In Genome-Editing Therapy Deal With Biogen, FDA Nod For Biohaven, Passage Bio IPO
© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.